Navigation Links
Mylan Announces XELODA® Settlement and License Agreement
Date:9/21/2011

PITTSBURGH, Sept. 21, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement and license agreement with Hoffman La Roche Inc. resolving litigation related to XELODA® Tablets, 150 mg and 500 mg, USP, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.

Pursuant to the agreement, the litigation was dismissed on Sept. 21, 2011.  Additional details are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. XELODA had U.S. sales of $570 million for the twelve months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the litigation settlement. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
2. Mylan Launches Generic Version of Uroxatral® Tablets
3. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
4. Mylan Launches First Generic Version of Entocort EC® Capsules
5. Mylan Receives Approval for Generic Version of Aricept® Tablets
6. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
7. Mylan Launches Generic Version of Roxicodone® Tablets
8. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
9. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
10. Mylan Launches First Generic Version of Amrix® Capsules
11. Mylan Launches Generic Version of Risperdal® M-Tab®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... --> --> ... Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, ... Ophthalmology, Gynecology) - Global Forecasts to 2020", published by ... forecast period of 2015 to 2020. The market is ... of 10.5% from 2015 to 2020. Browse ...
(Date:2/8/2016)... 2016 http://www.researchandmarkets.com/research/fqx6nz/global_skin ) ... Skin Protective Equipment Market 2016-2020" report to ... ) has announced the addition of the ... to their offering. --> ... the addition of the "Global Skin Protective ...
(Date:2/8/2016)... historic vote among its members this weekend, the Shinnecock Indian Nation voted ... dispensary on tribal land near Southampton . ... patients in the state,s Medical Cannabis Program. --> ... the state,s Medical Cannabis Program. --> Tribal members voted ... from the State of New York as a ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub ... According to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating ... balancing and detoxifying the body. , A former motivational speaker, Perry A~ has since ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home ... get to see the most incredible gardens and home improvement experts that attend this ... Convention Center - 700 14th St. Denver CO, is an exciting event that Performance ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/8/2016)... ... , ... The schedule is now online for the largest and ... is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give ... of chronic illness in children. , Very recent articles have cited 1 child in ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
Breaking Medicine News(10 mins):